Teknisk og drift
Denne siden fornyes snart!
Following further analysis of data, the company deems that there may be a risk that the information in a previous press release can be misinterpreted due to the term "Proof of Mechanism". The information is clarified by adding that the result that was presented is from a successful release study and that additional studies remain in order to achieve Proof of Mechanism.
On September 29th 2017 a press release was made concerning a study conducted using synthetic structural parts of XtriG. The result was positive as it showed a release of intact substance in saliva, which we see as valuable. Further analysis, made later on of data from this study as well as the results från previous binding studies, cannot confirm the chemical release that is a unique and important feature in this context. There is a risk that the information in the press release of 2017-09-29 is isinterpreted due to the term "Proof of Mechanism", which therefore should be clarified by adding that the result that was presented is from a successful release study and that additional studies remain in order to achieve Proof of Mechanism.
This information is information that NorInvent AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Paul Hasselgren (CEO, NorInvent AB) on January 17, 2018.
Paul HasselgrenCEO+46 760 49 40 email@example.com
NorInvent AB (publ)Medicon VillageSE-22381 LundSWEDEN+46 46 25 66 firstname.lastname@example.org
Ekstern link: http://www.aktietorget.se/NewsItem.aspx?ID=87209
Ekstern link: https://press.aktietorget.se/Norinvent/87209/778538.pdf
Nyheten er levert av Aktietorget.